Skip to main content

Table 2 Time course of ventilation parameters during the run-in phase

From: Feasibility and safety of low-flow extracorporeal CO2 removal managed with a renal replacement platform to enhance lung-protective ventilation of patients with mild-to-moderate ARDS

Parameter Baseline
(n = 20)
VT 5 ml/kg
(n = 20)
VT 4.5 ml/kg
(n = 20)
VT 4 ml/kg
(n = 19)a
Ventilation variable
 VT (ml/kg PBW)b 6.10 ± 0.30 5.04 ± 0.22c 4.49 ± 0.12c 3.98 ± 0.18c
 RR (breaths/min) 26 ± 4 26 ± 4 26 ± 4 25 ± 6
 PEEP (cmH2O)b 13.4 ± 3.6 13.4 ± 3.3 14.4 ± 3.3v 15.0 ± 3.4
 Pplat (cmH2O)b 26.3 ± 3.5 24.1 ± 3.0c 23.3 ± 2.8c 22.8 ± 2.6c
 Driving pressure (cmH2O)b 13.0 ± 4.8 10.7 ± 3.8v 8.9 ± 3.3v 7.9 ± 3.2c
 Compliance (ml/cmH2O) 33.8 ± 14.2 33.6 ± 12.7 36.0 ± 13.3 36.9 ± 13.4
 PaO2/FiO2 188 ± 75 192 ± 80 191 ± 71 184 ± 67
Blood gases
 pHb 7.39 ± 0.1 7.36 ± 0.10 7.34 ± 0.10c 7.32 ± 0.10c
 PaO2 (mmHg) 96 ± 36 93 ± 30 96 ± 24 89 ± 19
 PaCO2 (mmHg)b 43 ± 8 46 ± 7 49 ± 9c 53 ± 9c
 HCO3 (mmol/L) 26 ± 4 26 ± 4 27 ± 5 27 ± 4
 Lactate (mmol/L) 1.4 ± 0.6 1.2 ± 0.4 1.2 ± 0.5 1.2 ± 0.4
Patients on ECCO2R, nd 7 14 19
Patients with PaCO2 > 50 mmHg 2 9 9 11
ECCO2R
 Blood flow (ml/min) 424 ± 39 425 ± 38 421 ± 40
 Sweep-gas flow (L/min) 10 ± 0.3 10 ± 0.3 10 ± 0.3
 CO2 removal (ml/min) 51 ± 26
Hemodynamic
 Mean arterial pressure (mmHg) 76 ± 11 79 ± 20 76 ± 12 77 ± 19
 Heart rate (beats/min) 86 ± 15 85 ± 13 85 ± 14 83 ± 15
 Patients on norepinephrine 9 9 9 10
 Norepinephrine dose (μg/kg/min) 0.61 ± 1.10 0.55 ± 1.00 0.55 ± 0.99 0.50 ± 0.97
  1. Values presented as mean ± standard deviation or n (%)
  2. ECCO 2 R extracorporeal carbon-dioxide removal, FiO 2 fraction of inspired oxygen, HCO 3 bicarbonate, PaCO 2 partial alveolar carbon dioxide pressure, PaO 2 partial alveolar oxygen pressure, PBW predicted body weight, PEEP end-expiratory positive pressure, P plat plateau pressure, RR respiratory rate, VT tidal volume
  3. aOne patient’s PaCO2 increased > 20% at the VT 4.5 ml/kg step and did not undergo further VT reduction
  4. bp < 0.05, analysis of variance
  5. cp < 0.05 vs baseline
  6. dECCO2R initiated according to the study protocol when patients had a 20% increase in PaCO2 from baseline following VT decrease